2018 | 1 | 53-59
Article title

Carcinoembryonic antigen as a tumor marker in lung cancer – is it clinically useful?

Title variants
Languages of publication
Introduction. Lung cancer is the most common cancer in the Western world. Annually there are approximately 1.8 million new cases worldwide. It is characterized by poor prognosis with a 5-year survival of 10-17% depending on the country. Contributing to this poor prognosis is a mainly late diagnosis, as well as a fairly frequent recurrence despite radical surgery. Over the years, scientists have been searching for a tumor marker that would be useful for patients with lung cancer. Aim. The aim of this study is to discuss the significance of carcinoembryonic antigen (CEA) in the diagnosis, prognosis of the disease course, and monitoring patients with lung cancer. Methods. Review of the literature using the PubMed database, Termedia, Via Medica and the key issue: carcinoembryonic antigen as a tumor marker in lung cancer. Conclusions. Serum CEA level can be a reliable complement to the diagnosis of lung cancer. It can be helpful in preoperative prediction of disease course and qualification for adjuvant treatment of non-small cell lung cancer especially adenocarcinoma. Trends and normalization of CEA during chemotherapy have an impact on progression-free survival and overall survival (OS) of patients. Various available publications describe CEA as a marker for metastatic lung cancer, which is the most specific for metastasis in the liver and brain.
Physical description
  • Clinic of Clinical Oncology, Podkarpackie Oncology Center, Clinical Provincial Hospital No. 1 in Rzeszow, Poland
  • 2 Department of Oncology, Faculty of Medicine, University of Rzeszow, Poland
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.